MedTrace Logo

Ciprofloxacin/Celecoxib Combination in Patients With ALS

NCT04090684 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-02-01

No results posted yet for this study

Summary

This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures (ALSFRS-R and Vital Capacity).

Conditions

  • ALS (Amyotrophic Lateral Sclerosis)

Interventions

DRUG

Fixed dose combination Ciprofloxacin/Celecoxib

Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day

Sponsors & Collaborators

  • NeuroSense Therapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • Jeremy Shefner, MD, PhD · Barrow Neurological Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-09
Primary Completion
2021-09-27
Completion
2022-01-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04090684 on ClinicalTrials.gov